论文部分内容阅读
目的探讨维生素D受体(VDR)基因多态性与晚期非小细胞肺癌(NSCLC)化疗敏感性的关系。方法采用聚合酶链反应限制性片段长度多态性(PCR-RFLP)方法检测42例接受铂类药物化疗的晚期NSCLC患者VDR基因多态性,比较不同基因型对化疗敏感性的影响。结果化疗有效组Bsm1位点bb、Bb基因型分布频率分别为90.0%、10.0%;无效组分别为95.5%、4.5%。化疗有效组Apa1位点aa、Aa+AA基因型分布频率分别为45.0%、55.0%;无效组分别为40.9%、59.1%。化疗有效组Taq1位点Tt、TT基因型分布频率分别为10.0%、90.0%;无效组分别为4.5%、95.5%。两组无显著差异。结论 VDR基因Bsm1、Apa1、Taq1位点多态性与GP/GC方案化疗敏感性之间无相关。
Objective To investigate the relationship between vitamin D receptor (VDR) gene polymorphism and chemosensitivity in advanced non-small cell lung cancer (NSCLC). Methods Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to detect the polymorphism of VDR gene in 42 patients with advanced NSCLC treated with platinum-based chemotherapy. The effects of different genotypes on chemosensitivity were compared. Results The frequencies of bb and bb genotypes in Bsm1 site were 90.0% and 10.0% respectively in the chemotherapy-effective group and 95.5% and 4.5% in the invalid group respectively. The frequencies of aa and Aa + AA genotypes in Apa1 group were 45.0% and 55.0%, respectively; those in ineffective group were 40.9% and 59.1% respectively. The frequencies of Tt and TT genotypes in the Taq1-site of chemotherapy-effective group were 10.0% and 90.0%, respectively, while those in the invalid group were 4.5% and 95.5%, respectively. There was no significant difference between the two groups. Conclusion There is no correlation between VDR gene Bsm1, Apa1, Taq1 polymorphism and chemosensitivity of GP / GC regimen.